Dova Pharmaceuticals (NASDAQ:DOVA) – Equities research analysts at Leerink Swann lowered their Q2 2018 earnings per share (EPS) estimates for shares of Dova Pharmaceuticals in a research note issued to investors on Tuesday, May 22nd. Leerink Swann analyst G. Porges now anticipates that the company will post earnings per share of ($0.68) for the quarter, down from their prior forecast of ($0.63). Leerink Swann also issued estimates for Dova Pharmaceuticals’ Q3 2018 earnings at ($0.49) EPS, Q4 2018 earnings at ($0.32) EPS, FY2018 earnings at ($2.01) EPS, FY2019 earnings at $0.50 EPS, FY2020 earnings at $2.52 EPS and FY2021 earnings at $4.92 EPS.
A number of other equities research analysts also recently commented on DOVA. BidaskClub raised Dova Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, February 16th. Evercore ISI started coverage on Dova Pharmaceuticals in a research report on Friday, March 23rd. They issued a “line” rating and a $29.00 price objective for the company. Ladenburg Thalmann started coverage on Dova Pharmaceuticals in a research report on Thursday, April 26th. They issued a “buy” rating for the company. Zacks Investment Research downgraded Dova Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, April 27th. Finally, ValuEngine raised Dova Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $32.00.
Shares of NASDAQ:DOVA opened at $24.94 on Thursday. Dova Pharmaceuticals has a 52 week low of $16.98 and a 52 week high of $37.00.
Dova Pharmaceuticals (NASDAQ:DOVA) last announced its quarterly earnings data on Wednesday, May 9th. The company reported ($0.52) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.47) by ($0.05).
Large investors have recently made changes to their positions in the company. The Manufacturers Life Insurance Company grew its position in Dova Pharmaceuticals by 702.0% during the fourth quarter. The Manufacturers Life Insurance Company now owns 4,756 shares of the company’s stock valued at $137,000 after acquiring an additional 4,163 shares during the period. JPMorgan Chase & Co. grew its position in Dova Pharmaceuticals by 148.6% during the first quarter. JPMorgan Chase & Co. now owns 5,345 shares of the company’s stock valued at $145,000 after acquiring an additional 3,195 shares during the period. California State Teachers Retirement System purchased a new stake in Dova Pharmaceuticals during the third quarter valued at about $202,000. Jane Street Group LLC purchased a new stake in Dova Pharmaceuticals during the first quarter valued at about $220,000. Finally, Schwab Charles Investment Management Inc. purchased a new stake in Dova Pharmaceuticals during the third quarter valued at about $241,000. 35.93% of the stock is owned by institutional investors and hedge funds.
Dova Pharmaceuticals Company Profile
Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead drug candidate is avatrombopag that has completed Phase III clinical trials for the treatment of thrombocytopenia in patients with chronic liver disease.
Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.